TNFRSF9 and neoplasm: Chiu et al. showed that in humanized mouse models, efficient treatment with a PSMA- and CD3-specific bsAb required administration of a costimulatory agonistic 4-1BB in a high tumor burden condition, while no coadministration was required in a low tumor burden condition [141].